基于多组学胶原模型预测前列腺癌根治术后生化复发
本研究分析了55个胶原相关特征在转录组数据集(n=1393)中的预后价值,并在蛋白质组(n=69)和尿液肽组(n=73)中验证。多变量模型整合胶原转录本提高了预后准确性,优于临床变量;尿液胶原模型显示强预后潜力,但受样本量小限制。
要点
- 胶原相关转录本模型可提升RP术后BCR预测准确性
- 尿液胶原模型C-index为0.73,具无创预后潜力
- 组织胶原模型对总生存也有显著预后价值
核心结论
- 组织和尿液中的胶原相关分子特征可作为预测RP术后BCR的稳健预后生物标志物。
研究设计与样本
- 回顾性分析转录组数据集(n=1393)中55个胶原相关特征,并在蛋白质组(n=69)和尿液肽组(n=73)中验证。
- 使用Cox比例风险模型评估独立预后意义,并与临床指标基准比较。
主要发现
- 55个胶原相关转录本中11个与BCR显著相关(C-index:0.55-0.72,p < 0.002)。
- 多变量模型整合这些转录本后预后准确性超越临床变量(C-index:0.66-0.89,p < 0.002)。
- 蛋白质组验证确认5个关键胶原蛋白。
- 尿液胶原模型C-index为0.73(95% CI:0.62-0.85),显示强预后潜力。
- 组织胶原模型预测总生存C-index为0.59-0.70(p < 0.01)。
关键数值与推荐
- 胶原转录本单独预测BCR的C-index范围为0.55-0.72(p < 0.002)。
- 整合胶原转录本的多变量模型C-index范围为0.66-0.89(p < 0.002)。
- 尿液胶原模型C-index为0.73(95% CI:0.62-0.85)。
- 组织胶原模型预测总生存C-index为0.59-0.70(p < 0.01)。
临床怎么用
- 胶原模型可辅助RP术后BCR风险分层,尿液检测有望成为无创工具。
- 需进一步大样本验证后方可临床常规使用。
局限性
- 尿液验证队列样本量小(n=73)。
- 蛋白质组验证样本量有限(n=69)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The interplay between prostate cancer and the tumor microenvironment is well documented and of primary importance in disease evolution. Herein, we investigated the prognostic value of tissue and urinary collagen-related molecular signatures in predicting biochemical recurrence (BCR) after radical prostatectomy (RP). METHODS: A comprehensive analysis of 55 collagen-related features was conducted using transcriptomic datasets (n = 1393), with further validation at the proteomic level (n = 69). Additionally, a distinct cohort (n = 73) underwent a urine-based peptidomic analysis, culminating in the validation of a urine-derived prognostic model. Independent prognostic significance was assessed using Cox proportional hazards modeling, while the model's predictive performance was benchmarked against established clinical metrics. KEY FINDINGS AND LIMITATIONS: An expression analysis of 55 collagen-related transcripts identified 11 transcripts significantly associated with BCR (C-index: 0.55-0.72, p < 0.002). Multivariable models incorporating these transcripts enhanced prognostic accuracy, surpassing clinical variables (C-index: 0.66-0.89, p < 0.002). Proteomic validation confirmed five key collagen proteins, while a urine-based collagen model (C-index: 0.73, 95% confidence interval: 0.62-0.85) demonstrated a strong prognostic potential, although limited by small patient numbers. Additionally, tissue collagen-based models predicted overall survival with a significant prognostic value (C-index: 0.59-0.70, p < 0.01). CONCLUSIONS AND CLINICAL IMPLICATIONS: Collagen-based molecular signatures in both tissue and urine emerge as robust prognostic biomarkers for predicting BCR following RP.
引用
- Frantzi M, Tymoszuk P, Salcher S, et al. Prediction of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy by Collagen Models Using Multiomic Profiles. Eur Urol Oncol. 2025. PMID: 40312179. doi:10.1016/j.euo.2025.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。